* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Female Reproductive Cycle I
Magnesium in biology wikipedia , lookup
Specialty drugs in the United States wikipedia , lookup
Orphan drug wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Neuropharmacology wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Prescription costs wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Pharmacognosy wikipedia , lookup
Drug interaction wikipedia , lookup
Pregnancy and Preterm Labor Drugs A&P of female reproductive system Feedback loop (pg. 808) Altered hepatic metabolism of drugs Reduced GI motility Increased GI pH Increased GFR-more rapid excretion Expanded blood volume = dilution Alteration in drug clearance • Implications: Drug dosages and dosing intervals should be considered Allows for the exchange of many substances including medications Speed of exchange/transfer varies • Maternal and fetal blood flow • Molecular weight of the substance being • • • • exchanged Degree of ionization (does it have a charge) Degree of protein binding (↑ do not cross readily) Metabolic activity of the placenta Maternal dose Risk/Benefits MD/NP must consider the aforementioned physiological changes Liver metabolism is slower What we give the mother can have prolonged effects on the fetus Impact fetal outcome Remember the ways that drugs cross the placenta—same can be applied to breast tissue. Know drugs that accumulate in the breast tissue because these drugs can be transported to the infant during feeding. Your role in teaching the mother cannot be underestimated. Legal and illicit drugs Mother’s underlying conditions still need to be treated • Seizure disorders • Diabetes • HTN OTC drugs • Cold remedies, stool softeners, pain medications FDA Category system-revisit Terat/o – greek monster -gen = to produce Substances that are teratogenic are those that produce birth defects/developmental abnormalities Period of possibility begins 2 weeks after conception Weeks 2-10 organogenesis Timing, dose and duration of exposure Review PTL that progresses to PTD accounts for most prenatal morbidity and mortality in US (excluding fetal abnormalities) No one cause • Younger than 18 but • • • • • older than 40 Low SES Previous hx of PTL Intrauterine infections Polyhyraminos Multiple gestation • Uterine abnormalities • Antepartum hemorrhage • Smoking • Incompetent cervix • UTI Goal is to stop the preterm labor Tocolytics Contraindicated in: • Pregnancy ↓ 20 wks gestation (ultrasound) Considered a miscarriage • Bulging or PROM • Confirmed fetal death or anomalies incompatible with life • Maternal hemorrhage and severe fetal compromise • Chorioamnionitis Beta2 agonists (Beta Sympathomimetics) • Terbutaline (Brethine) Recall Table 17-1 Page 268 Beta2 receptors are located in uterus An agonist produces a response Giving a Beta2 agonist will relax the uterus Giving a Beta2 antagonist (Beta-Blocker) would have the opposite effect. Calcium antagonist • Magnesium Sulfate (Mag Sulfate) Interrupt uterine contractions to provide additional time in utero Delay delivery so corticosteroids can be given to promote fetal lung maturity Allow safe transport to another facility if needed SQ/oral/IV Minimally protein bound Half life 11-16 hours IV/SQ • Onset 15 minutes • Peak 30-60 minutes • Duration 1-4 hours (SQ) Assessment Diagnosis Plan Interventions Evaluation Review 822 Calcium antagonist (blocks response) CNS depressant ***** Fewer side effects than Brethine Given IV Dose is titrated to keep contractions under control Need to draw magnesium levels Contraindicated –myasthenia gravis, impaired kidney function, recent MI Low blood pressure Flushing Sweating Dizziness Nausea Headache Lethargy Slurred Speech Increased pulse rate Assess for neuro, respiratory or cardiac depression. Antidote: Calcium Gluconate (10 mg IV Push over 3 minutes) Assess magnesium levels 4-7 mg/dL Loss of patellar reflexes often first sign of toxicity-8-10 mEq/L Respiratory depression-Levels greater than 10-15 mEq/L Cardiac Arrest-Levels greater that 20-25mEq/L Page 827 Assess and monitor-Respirations, FHR, fetal activity, I&O, breath and bowel sounds, DTR, weight, have antidote on hand--- Diagnose Plan Implement Evaluate Clients at risk for PTL Accelerates lung maturation and lung surfactant development Decreases RSD Increases survival L/S ratio predicts fetal lung maturation • Lecithin/sphingomyelin Betamethasone (Celestone) • Seizures, headache, HTN, petechiae, ecchymoses, facial redness Dexamethasone • Insomnia, nervousness, increased appetite, arthralgia, hypersensitivity reactions • See Nursing Process for Betamethasone pg. 823 Elevated BP without proteinuria after 20 wks. Had normal BP to begin with. Categories of GHTN Preeclampsia: Gestational hypertension with proteinuria. Eclampsia: New-onset grand mal seizures in client with preeclampsia. Systolic greater than 140mm/Hg or diastolic greater than 90mm/Hg Proteinuria greater than 300mg in a 24 hour urine collection After 20th week Graded as mild to severe Hemolysis Elevated Liver Enzymes Low Platelet Count Uncomplicated delivery Psychological support for client/family Reduction of vasospasm Prevention of seizures Delivery methyldopa (Aldomet) hyralazine (Apresoline) labetalol (Trandate) Beta-blockers Prazosin Nifedipin Clonidine ALTERNATIVES FIRST LINE